# Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC

> **NCT07399015** · — · NO_LONGER_AVAILABLE · sponsor: **Endevica Bio**

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Unresectable Pancreatic Ductal Adenocarcinoma
- Metastatic PDAC

## Interventions

- **DRUG:** mifomelatide

## Key facts

- **NCT ID:** NCT07399015
- **Lead sponsor:** Endevica Bio
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07399015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07399015, "Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07399015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*